Table 1 Clinical and laboratory characteristics of patients
| Â | Â | All patients | Anti-CCP | P value | |
|---|---|---|---|---|---|
| Â | Â | Â | Negative | Positive | Â |
Age | <50* | 45 (75%) | 8 (17.8%) | 37 (82.2%) | NS |
|  | ≥50 | 15 (25%) | 2 (13.3%) | 13 (86.7%) |  |
Sex | female | 54 (90%) | 9 (16.7%) | 45 (83.3%) | NS |
| Â | male | 6 (10%) | 1 (16.7%) | 5 (83.3%) | Â |
Duration | <6m | 3 (5%) | 1 (33.3%) | 2 (66.7%) | NS |
|  | ≥6m | 57 (95%) | 9 (15.8%) | 48 (84.2%) |  |
Smoking | yes | 5 (8.3%) | 1 (20%) | 4 (80%) | NS |
| Â | no | 55 (91.7%) | 9 (16.4%) | 46 (83.6%) | Â |
CRP | <18 * | 26 (43.3%) | 7 (26.9%) | 19 (73.1%) | NS |
|  | ≥18 | 34 (56.7%) | 3 (8.8%) | 31 (91.2%) |  |
RF | +ve | 43 (71.7%) | 4 (9.3%) | 39 (90.7%) | 0.02 |
| Â | Â | Â | 6 (35%) | 11 (65%) | Â |
ESR-1 | <32 * | 14 (23.3%) | 5 (35.7%) | 9 (64.3%) | 0.04 |
|  | ≥32 | 46 (76.7%) | 5 (10.9%) | 41 (89.1%) |  |
ANA | +ve | 22 (36.7%) | 0 (0%) | 22 (100%) | 0.03 |
| Â | -ve | 38 (63.3%) | 10 (40.8%) | 28 (59.2%) | Â |
AKA | +ve | 31 (52%) | 3 (10%) | 28 (90%) | Â |
| Â | -ve | 29 (48%) | 17 (59%) | 12 (41%) | 0.05 |
Grade of activity (DAS) | Â | Â | Â | Â | Â |
   - Mild or moderete |  | 25 (41.7%) | 9 (31.6%) | 16 (68.4%) | 0.001 |
   - Severe |  | 35 (58.3%) | 1 (9.8%) | 34 (90.2%) |  |
Larsen score | <35* | 19 (31.7%) | 6 (10%) | 13 (21.7%) | 0.05 |
|  | ≥35 | 41(68.3%) | 4 (6.7%) | 37 (61.7%) |  |
HLA-DRB1*04 | +ve | 21 (35%) | 2 (9.5%) | 19 (90.5%) | NS |
| Â | -ve | 39 (65%) | 8 (20.5%) | 31 (79.5%) | Â |
HLA-RB1*01 | +ve | 27 (45%) | 5 (19%) | 22 (81%) | NS |
| Â | -ve | 33 (55%) | 5 (15%) | 28 (85%) | Â |